-
-
-
-
-
-
-
Needham Reiterates Buy Rating on Lucid Diagnostics Inc (LUCD)
-
-
-
-
-
-
-
Wedbush Upgrades Replimune Group (REPL) to Outperform
-
-
-
-
-
-
-
The Lancet publishes Capricor's phase 3 DMD therapy trial results
-
-
-
-
-
-
-
H.C. Wainwright on Capricor Therapeutics (CAPR): 'Cage Match Expected at Wednesday's AdCom as Drama with FDA Continues'
-
-
-
-
-
-
-
FDA accepts Axsome drug application for cataplexy treatment
-
-
-
-
-
-
-
BMO Capital Upgrades Replimune Group (REPL) to Outperform
-
-
-
-
-
-
-
FDA advisory panel votes 9-0 in favor of Moderna's mRNA flu vaccine
-
15,912 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

